Kennedy Capital Management LLC Buys 62,077 Shares of DexCom, Inc. $DXCM

Kennedy Capital Management LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 593.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 72,544 shares of the medical device company’s stock after buying an additional 62,077 shares during the period. Kennedy Capital Management LLC’s holdings in DexCom were worth $4,815,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in DexCom in the 4th quarter worth about $483,356,000. Holocene Advisors LP acquired a new stake in DexCom in the 3rd quarter worth about $163,964,000. CIBC Private Wealth Group LLC raised its stake in DexCom by 374.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after purchasing an additional 2,294,709 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in DexCom in the 4th quarter worth about $86,088,000. Finally, Neuberger Berman Group LLC raised its stake in DexCom by 111.6% in the 4th quarter. Neuberger Berman Group LLC now owns 2,340,199 shares of the medical device company’s stock worth $155,319,000 after purchasing an additional 1,234,469 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on DXCM. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Barclays reiterated an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

Insider Activity at DexCom

In related news, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 40,994 shares of company stock worth $2,919,022 over the last three months. 0.28% of the stock is owned by insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $74.22 on Tuesday. The firm has a 50 day moving average of $66.37 and a 200-day moving average of $67.68. The stock has a market capitalization of $28.64 billion, a PE ratio of 31.72, a PEG ratio of 1.18 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.